Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in alzheimer's disease and vascular dementia

Neurochemical Research

Volumn 37, Issue 7, 2012, Pages 1554-1559

  Uslu, Sema ^a   Akarkarasu, Zubeyde Eken ^a   Ozbabalik, Demet ^a   Ozkan, Serhat ^a   Çolak, Omer ^a   Demirkan, Emine Sutken ^a   Ozkiris, Ayşe ^a   Demirustu, Canan ^a   Alatas, Ozkan ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Alzheimer's disease; Amyloid b42; Interleukin 6; TNF a; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84862883254     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0750-0     Document Type: Article

References (39)

1. Lee YJ, Han SB, Nam SY et al (2010) Inflammation and alzheimer's disease. Arch Pharm Res 33:1539-1556
2. Moretti A, Gorini A, Villa RF (2011) Pharmacotherapy and prevention of vascular dementia. CNS Neurol Disord Drug Targets 10:370-390
3. Arslantaş D, Ozbabalik D, Metintaş S et al (2009) Prevalence of dementia and associated risk factors in Middle Anatolia, Turkey. J Clin Neurosci 16:1455-1459
4. McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer's disease. Neurology 34: 939-944
5. Roman GC, Tatemichi TK, Erkinjuntti T et al (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop. Neurology 43:250-260
6. Kawarabayashi T, Shoji M (2008) Plasma biomarkers of alzheimer's disease. Curr Opin Psychiatry 21:260-267
7. Tuppo EE, Arias HR (2005) The role of inflammation in alzheimer's disease. Int J Biochem Cell Biol 37:289-305
8. Heneka MT, O'Banion MK, Terwel D et al (2010) Neuroinflammatory processes in alzheimer's disease. J Neural Transm 117:919-947
9. Teunissen CE, de Vente J, Steinbusch HW et al (2002) Biochemical markers related to alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23(4):485-508
10. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364:91-112
11. Qiu WQ, Sun X, Selkoe DJ et al (2007) Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 22:536-542
12. Cosentino SA, Stern Y, Sokolov E et al (2010) Plasma ß-amyloid and cognitive decline. Arch Neurol 67:1485-1490
13. Sun X, Bhadelia R, Liebson E et al (2011) The relationship between plasma amyloid-b peptides and the medial temporal lobe in the homebound elderly. Int J Geriatr Psychiatry 26:593-601
14. Sundelöf J, Giedraitis V, Irizarry MC et al (2008) Plasma beta amyloid and the risk of alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65:256-263
15. Graff-Radford NR, Crook JE, Lucas J et al (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64:54-362
16. van Dijk EJ, Prins ND, Vermeer SE et al (2004) Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55:570-575
17. Schupf N, Tang MX, Fukuyama H et al (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105:14052-14057
18. Seppälä TT, Herukka SK, Hänninen T et al (2010) Plasma Abeta42 and Abeta40 as markers of cognitive change in followup: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81:1123-1127
19. van Oijen M, Hofman A, Soares HD et al (2006) Plasma Abeta( 1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5:655-660
20. Bibl M, Esselmann H, Mollenhauer B et al (2007) Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 103:467-474
21. Meyer JS, Xu G, Thornby J et al (2002) Is mild cognitive impairment prodromal for vascular dementia like alzheimer's disease? Stroke 33:1981-1985
22. Zuliani G, Ranzini M, Guerra G et al (2007) Plasma cytokines profile in older subjects with late onset alzheimer's disease or vascular dementia. J Psychiatr Res 41:686-693
23. Licastro F, Pedrini S, Caputo L et al (2000) Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103:97-102
24. Zuliani G, Guerra G, Ranzini M et al (2007) High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int JGeriatr Psychiatry 22:305-311
25. Angelis P, Scharf S, Mander A et al (1998) Serum interleukin-6 and interleukin-6 soluble receptor in alzheimer's disease. Neurosci Lett 244:106-108
26. Swardfager W, Lanctôt K, Rothenburg L et al (2010) A metaanalysis of cytokines in alzheimer's disease. Biol Psychiatry 68:930-941
27. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, Gerlo S (2011) Interleukin-6, a mental cytokine. Brain Res Rev 67:157-183
28. Engelhart MJ, Geerlings MI, Meijer J et al (2004) Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 61:668-672
29. Tarkowski E, Blennow K, Wallin A et al (1999) Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in alzheimer disease and vascular dementia. J Clin Immunol 19:223-230
30. Park KM, Bowers WJ (2010) Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22:977-983
31. Paganelli R, Di Iorio A, Patricelli L et al (2002) Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate alzheimer's disease patients. Exp Gerontol 37:257-263
32. Alvarez A, Cacabelos R, Sanpedro C et al (2007) Serum TNFalpha levels are increased and correlate negatively with free IGFI in alzheimer disease. Neurobiol Aging 28:533-536
33. van Exel E, Eikelenboom P, Comijs H et al (2009) Vascular factors and markers of inflammation in offspring with a parental history of late-onset alzheimer disease. Arch Gen Psychiatry 66: 1263-1270
34. Magaki S, Mueller C, Dickson C et al (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42:233-240
35. Yasutake C, Kuroda K, Yanagawa T et al (2006) Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 256:402-406
36. Whitmer RA, Gunderson EP Jr, Quesenberry CP et al (2007) Body mass index in midlife and risk of alzheimer disease and vascular dementia. Curr Alzheimer Res 4:103-109
37. Chen YC, Chen TF, Yip PK et al (2010) Body mass index (BMI) at an early age and the risk of dementia. Arch Gerontol Geriatr 50(SUPPL. 1):S48-S52
38. Anstey KJ, Cherbuin N, Budge M et al (2011) Body mass index in midlife and late-life as a risk factor for dementia: a metaanalysis of prospective studies. Obes Rev 12:426-437
39. Beydoun MA, Beydoun HA, Wang Y (2008) Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev 9:204-218